Allogeneic NK cell therapy (Instituto de Investigación Hospital Universitario La Paz)

异基因NK细胞疗法(Instituto de Investigación Hospital Universitario La Paz)

Report date: 2022/09/06 18:12:13

Base Information

Drug NameAllogeneic NK cell therapy (Instituto de Investigación Hospital Universitario La Paz)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstituto De Investigación Hospital Universitario La Paz
China Registration ClassN/A

Develop Information

Active CompaniesInstituto De Investigación Hospital Universitario La Paz
Inactive CompaniesN/A
Active IndicationsCoronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A